A Data Driven Approach to Profile Potential SARS-CoV-2 Drug Interactions Using TylerADE
Robert P. Schumaker, Michael A. Veronin, Trevor Rohm, Matthew Boyett, Rohit Dixit
Abstract
We use a data driven approach on a cleaned adverse drug reaction database to determine the reaction severity of several covid-19 drug combinations currently under investigation. We further examine their safety for vulnerable populations such as individuals 65 years and older. Our key findings include 1. hydroxychloroquine/chloroquine are associated with increased adverse drug event severity versus other drug combinations already not recommended by NIH treatment guidelines, 2. hydroxychloroquine/azithromycin are associated with lower adverse drug event severity among older populations, 3. lopinavir/ritonavir had lower adverse reaction severity among toddlers and 4. the combination of azithromycin, hydroxychloroquine and tocilizumab is safer than its component drugs. While our approach does not consider drug efficacy, it can help prioritize clinical trials for drug combinations by focusing on those with the lowest reaction severity and thus increase potential treatment options for covid-19 patients.